Zepp Health Corporation’s SEC filings document a foreign private issuer whose American depositary shares each represent sixteen Class A ordinary shares. The company files current reports on Form 6-K and annual reporting on Form 20-F covering its smart wearable and health technology business, including Amazfit-branded products and the Zepp Digital Management Platform.
The filings and exhibits record unaudited operating results, revenue and margin commentary, cash, inventory and loan balances, product launches, capital-structure actions, risk factors, governance matters and ADR-related disclosure. They also provide formal disclosure around periodic results releases and other material information furnished by the company to U.S. markets.
Zepp Health Corp’s Chief Financial Officer, Deng Cheng, reported compensation-related equity activity involving American depositary shares (ADSs) and restricted share units (RSUs). On June 26, 2026, 366,000 RSUs, each representing one Class A ordinary share, vested and were settled into ADSs, with each ADS representing 16 Class A ordinary shares. This conversion delivered 22,875 ADSs at no cost to the CFO.
On the same date, 9,836 ADSs were sold in the open market at a weighted average price of $4.61 per ADS in a sell-to-cover transaction to pay tax withholding obligations tied to the RSU vesting. Following these transactions, the CFO directly holds 114,539 ADSs, indicating that most of the vested equity was retained as ongoing ownership.
Zepp Health Corp Schedule 13G filing reports that Morgan Stanley (through reporting units) beneficially holds 8,472,224 Class A Ordinary Shares / ADRs, representing 7.5% of the class. The filing lists shared voting power of 8,472,128 and shared dispositive power of 8,472,224, and is signed by an authorized Morgan Stanley signatory.
Zepp Health Corporation submitted a Rule 144 notice reporting securities to be sold in connection with the vesting of Restricted Share Units under its Share Incentive Plan. The filing references ADRs (each representing 16 Class A ordinary shares) and a vesting date of 06/26/2026.
The filing lists numeric fields including 9,836 and other reported figures. The entry identifies the ADR class and the vesting event; timing and the connection to the Share Incentive Plan are stated verbatim.
Zepp Health reported a strong start to 2026, with first‑quarter revenue rising 33.8% year over year to US$51.5 million, driven by new Amazfit products such as Active Max, Active 3 Premium, and T‑Rex Ultra 2. Amazfit‑branded revenue also grew 33.8% year over year, reflecting continued progress in its shift toward premium, Hybrid Training‑focused wearables.
Gross margin improved year over year to 37.7%, producing gross profit of US$19.4 million, but Zepp still posted a GAAP net loss of US$19.6 million and an adjusted net loss of US$17.9 million, both slightly narrower than a year ago. Cash and restricted cash totaled US$103.2 million and inventory fell to US$62.8 million, while cumulative debt retired since 2023 reached US$46.4 million. For the second quarter of 2026, management guides net revenue to US$63.0–68.0 million, implying about 6–14% growth versus the same quarter of 2025.
Zepp Health Corp reports an amended Schedule 13G/A showing 11,477,632 shares of Class A common stock beneficially owned, equal to 10.0% of the class as of 03/31/2026. The filing identifies FIL Limited and affiliated entities as the reporting holders.
The disclosure states that Fidelity Funds - China Focus holds 5,998,048 shares or 5.2% of Class A common stock as of 03/31/2026. Signatures show transactions are reported via power of attorney and include Exhibit 99 references.
Zepp Health Corporation files its annual report detailing a global smart wearables and health-technology business built around Amazfit, Zepp Clarity and Zepp Aura brands. For 2025, it generated $258.9M in revenue and reported a net loss of $40.1M.
The company operates through a Cayman holding structure with significant activities in China conducted via consolidated VIEs, whose revenue contribution fell from 40.1% in 2023 to 8.0% in 2025. Zepp highlights legal and operational risks from PRC regulation, VIE enforceability, data security oversight, and potential impacts of the HFCAA on U.S. trading.
Zepp changed its reporting currency from Renminbi to U.S. dollars in 2024 and effected an ADS ratio change so that one ADS now represents 16 Class A shares. As of December 31, 2025, it had 135,608,316 Class A and 99,277,687 Class B ordinary shares outstanding.
Zepp Health Corp director Xie Bing (Brian) has filed an initial statement of beneficial ownership on Form 3. The filing establishes his status as a director and does not report any insider buy, sell, or other share transactions.
Zepp Health Corp director Lai Jimmy Y. filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting insider under securities rules and does not report any stock purchases, sales, or other transactions in Zepp Health shares.
Zepp Health Corp Chief Technology Officer Meihui Fan has filed an initial statement of beneficial ownership, detailing existing equity and option interests rather than new trades. The filing lists several option awards over Class A ordinary shares with a conversion or exercise price of US$0.0000, covering 160,000, 200,000, 80,000 and 80,000 underlying Class A shares with expirations between 2031 and 2034. It also reports indirect holdings of 432,000 Class A ordinary shares and 3,450,746 Class B ordinary shares held by Fandler Holding Limited, which is ultimately owned by a trust for Mr. Fan and his family members. In addition, Mr. Fan directly holds 10,000 American depositary shares, with each ADS representing 16 Class A ordinary shares.
Zepp Health Corp Chief Financial Officer Deng Cheng filed an initial ownership report on Form 3, showing direct holdings of 101,500 American depositary shares (ADSs). Each ADS represents 16 Class A ordinary shares, meaning this filing simply discloses his existing equity stake rather than reporting a new stock transaction.